News AZ, Amgen positive Ph3 results for Tezspire in EoE AstraZeneca and Amgen have announced the first Phase III results for Tezspire (tezepelumab) in eosinophilic oesophagitis (EoE).
News Amgen and UCB re-file Evenity for US approval Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s pre
News Avacta hoping to disrupt antibody drug dominance Avacta is one of several biotechs turning their backs on mabs.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
